Exact Sciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Exact Sciences, Lowers Price Target to $72
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $70
Exact Sciences Analyst Ratings
Exact Sciences Corp: TD Cowen cuts price target from $100 to $80
Analysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)
Piper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Canadian Investment Banking Group: Maintaining the Exact Sciences (EXAS.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $90.00 to $85.00.
Exact Sciences Analyst Ratings
Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $80
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth Initiatives
Buy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative Pipeline
Buy Rating Affirmed for Exact Sciences on Promising Multi-Cancer Detection Technology
Exact Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Buy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement Prospects
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)